Short-term mechanical circulatory support (MCS) has been increasingly utilized for both left and/or right ventricular failure. The CentriMag ventricular assist support system is associated with ease of implant, high flow capacities that allow adequate unloading conditions and low risk of thrombosis. We describe our single-center experience since CentriMag was adopted as our institutional device of choice for short-term MCS. All consecutive adult patients who had a CentriMag pump implanted for any indication between May/2012-Dec/2013 were reviewed. Indications, pre-operative risk profile, surgical data and outcomes were evaluated. Survival was computed from CentriMag explant to last follow-up clinic visit up to May 10, 2014. Data is presented as median (range). Fourteen patients [11 males, age 46 (18-76) years, body mass index 27 (16-36), creatinine 88 (88-265) μmol/L, modified Model for End-Stage Liver Disease 15 (6-26) points] were supported with 18 CentriMag pumps, as described in Table 1. The most common indication was right ventricular failure at the time of or after implantation of a long-term continuous-flow left ventricular assist device (LVAD). Pre-CentriMag MCS included 1 extracorporeal membrane oxygenation (ECMO) and 4 intra-aortic balloon pumps; 5 patients were on mechanical ventilation. All 4 CentriMag LVAD had left atrial inflow cannulation and 8 devices were implanted off-pump. Median time of CentriMag support was 14 (1-119) days. No CentriMag pump exchange was required. An oxygenator was added to the circuit in 2 cases to facilitate ECMO. No strokes or thromboembolic events were observed. Survival to hospital discharge was 71% for all patients and 80% when excluding cases of post-cardiotomy shock. Among patients who were supported with CentriMag right ventricular assist device (RVAD) in the context of biventricular assist device (BiVAD), survival was 78%. At a median post-explant follow-up of 318 (51-707) days, all 10 survivors to hospital discharge were alive (5 transplanted, 1 recovered, 1 listed for transplant and 1 long-term LVAD supported as bridge-to-candidacy). Three deaths were attributed to multisystem organ failure and/or sepsis and 1 to decannulation of right atrium. In our experience, the CentriMag is associated with successful outcomes in high risk individuals with low rates of device-related complications.